Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00894543 · ClinicalTrials.gov registry record · NA
MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women
A NA study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 205
- Enrollment target
NCT00894543: Completed NA study, sponsored by Fred Hutchinson Cancer Center.
NCT00894543 is a NA study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 205 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00894543, a NA study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 205 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether a medication reduces the number, severity and bothersomeness of menopausal hot flashes. Escitalopram (also called Lexapro®) is a selective serotonin reuptake inhibitor (SSRI). It is sold by prescription for depression and general anxiety disorder. An SSRI increases serotonin, a brain substance that is believed to influence mood. Serotonin may also affect brain levels of estradiol, a hormone related to hot flashes. This research study will test whether escitalopram reduces menopausal hot flashes.
Primary Outcome
Baseline hot flash frequency per day was calculated as the daily mean of the daily totals reported during the first two screening weeks.
Interventions
- OTHER Placebo
- DRUG Escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-06 |
| Phase | NA |
What the finished NCT00894543 record still lists
NCT00894543 is an interventional study that assigns participants to a tested intervention. The registered 205 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00894543 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00894543 about?
NCT00894543 is a clinical study titled "MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women". The purpose of this study is to test whether a medication reduces the number, severity and bothersomeness of menopausal hot flashes. Escitalopram (also called Lexapro®) is a selective serotonin reuptake inhibitor (SSRI). It is sold by prescription for depression and general anxiety disorder. An SSRI...
What is the current status of trial NCT00894543?
This trial is currently completed. It is a NA study. The enrollment target is 205 participants. The study started on 2009-07. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00894543?
The interventions under investigation include: Placebo (OTHER), Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00894543?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00894543's enrollment target sits among peer trials
205 499th of 2000 higher than 1,501 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03457493 · 205 participants · Phase 1
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
- NCT05134857 · 205 participants · Phase 2
The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
- NCT05181891 · 205 participants · Phase 2
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
- NCT05283811 · 205 participants · NA
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia